含利奈唑胺联合方案治疗耐多药结核病患者的效果分析

Efficacy analysis of linezolid-containing regimen in the treatment of multidrug-resistant tuberculosis patients

目的分析含利奈唑胺联合方案治疗耐多药结核病患者的临床效果。方法 75例耐多药结核病患者,随机分为对照组(37例)和研究组(38例)。对照组患者采用吡嗪酰胺、丙硫异烟胺、左氧氟沙星及乙胺丁醇联合方案治疗,研究组在对照组基础上增加利奈唑胺治疗,比较两组患者痰菌转阴情况、病灶吸收情况及不良反应发生情况。结果治疗后,研究组痰菌转阴率为92.11%,高于对照组的72.97%,差异有统计学意义(P<0.05)。研究组病灶吸收率为94.74%,高于对照组的78.38%,差异有统计学意义(P<0.05)。研究组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论针对耐多药结核病患者采用含利奈唑胺联合方案治疗效果显著,可提高患者痰菌转阴率及病灶吸收率,值得临床推广使用。

Objective To analyze the clinical effect of linezolid-containing regimen in the treatment of multidrug-resistant tuberculosis patients. Methods A total of 75 multidrug-resistant tuberculosis patients were randomly divided into control group(37 cases) and research group(38 cases). The control group was treated with pyrazinamide, propionate isoniazid, levofloxacin and ethambutol, and the research group was treated with linezolid on the basis of the control group. Comparison were made on negative conversion rate of bacteria in sputum,absorption of lesions and occurrence of adverse reactions between the two groups. Results After treatment, the research group had higher negative conversion rate of bacteria in sputum as 92.11% than 72.97% in the control group, and the difference was statistically significant(P<0.05). The research group had higher absorption of lesions as 94.74% than 78.38% in the control group, and the difference was statistically significant(P<0.05). The research group had no statistically significant difference in incidence of adverse reactions compared with the control group(P>0.05). Conclusion Linezolid-containing regimen shows remarkable effect in the treatment of multidrugresistant tuberculosis patients, and it can improve negative conversion rate of bacteria in sputum and absorption of lesions. It is worthy of clinical promotion and application.